Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants

@article{Exner2019EffectOA,
  title={Effect of an activated charcoal product (DOAC Stop{\texttrademark}) intended for extracting DOACs on various other APTT-prolonging anticoagulants},
  author={Thomas Exner and Monica Ahuja and Lisa Ellwood},
  journal={Clinical Chemistry and Laboratory Medicine (CCLM)},
  year={2019},
  volume={57},
  pages={690 - 696}
}
Abstract Background The aim of the study was to investigate the specificity of an activated charcoal-based product (DOAC Stop™) initially intended for the specific extraction of direct oral anticoagulants (DOACs) from test plasmas on a range of other anticoagulants. Methods Test plasmas were prepared by adding various anticoagulants to pooled normal plasma at concentrations prolonging an activated partial thromboplastin time (APTT) test by a factor of 1.5–3. These plasmas were treated with DOAC… Expand
View on Wolters Kluwer
ncbi.nlm.nih.gov
17 Citations
Background Citations
1
Methods Citations
1
Results Citations
1

17 Citations

Citation Type

Citation Type

The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays
TLDR
Most of the activated carbon (AC) products reviewed here appear to remove DOACs from test plasmas without significantly affecting underlying clotting tests and permit correct diagnosis of various haemostatic conditions despite the initial presence ofDOACs. Expand
A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC‐Remove
TLDR
This study describes the use of a simple charcoal product (DOAC‐RemoveTM) to allow haemostasis assays on patients taking direct oral anticoagulants ( DOAC) and how this algorithm aids diagnostic accuracy. Expand
Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.
TLDR
Results indicate that dRVVT (especially LA Confirm) and similar tests might be useful for determining DOAC concentrations more reliably and with better sensitivity than currently possible with clotting tests. Expand
Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection.
TLDR
Overall, in vitro DOAC absorbance by active charcoal compounds is a useful laboratory tool for LA-detection in patients on DOAC, although caution should however be exerted when used in daily practice. Expand
Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban
  • L. Slavík, J. Jáčová, +5 authors M. Palová
  • Medicine
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2019
TLDR
The DOAC laboratory balancing procedure DOAC-Stop was evaluated by its own high-performance liquid chromatography-coupled tandem mass spectrometrymethod, which simultaneously sets all high-sensitivity DOACs. Expand
Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
TLDR
DOACs should not be routinely used in antiphospholipid syndrome patients, especially in those with a high-risk profile (triple positivity to aPL, arterial thrombosis, and recurrentThrombotic events). Expand
Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa.
TLDR
DOAC Stop was able to neutralise the false LA activity induced by rivaroxaban, both in terms of clot-times and LA ratios, and required additional testing to investigate prolonged clotting times. Expand
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
TLDR
The information in this manuscript supplements the previous ICSH DOAC laboratory guidance document and is based on information from peer-reviewed publications about laboratory measurement of DOACs, contributing author's personal experience/expert opinion and good laboratory practice. Expand
Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing—Review of the literature and evaluation on spiked and patient samples
TLDR
DOAC‐Stop (D‐S) represents a preanalytical strategy to cope with this issue of direct oral anticoagulant interference with lupus anticoAGulant testing. Expand
Clinical protocols for oral anticoagulant reversal during high risk of bleeding for emergency surgical and nonsurgical settings: a narrative review.
TLDR
The present algorithms propose a tool to help health care providers in the best decision making for patients under emergency conditions and are presented as clinical protocols for practical use. Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Simple method for removing DOACs from plasma samples.
TLDR
DOAC Stop reduces the false positivity for lupus anticoagulants observed in dilute Russells viper venom time (dRVVT) tests on DOAC-containing plasmas and could be useful for eliminating unwanted effects of DOACs on routine coagulation testing. Expand
The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement
TLDR
It is shown that for the determination of ACT in CPB where high dose aprotinin therapy is used only ACT determinations with machines using kaolin as activator yield accurate results. Expand
Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests
TLDR
The DOAC-Stop® adsorbent procedure appeared to be an effective and simple way to overcome the interference of DOAC on coagulation tests and should facilitate the interpretation of thrombophilia screening tests in patients taking DOACs. Expand
Antidotes for novel oral anticoagulants: current status and future potential.
TLDR
Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal and are currently in premarketing studies. Expand
Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
TLDR
Results suggest that activated charcoal may be useful in the management of apixaban overdose or accidental ingestion, andAdministration of activated charcoal up to 6 h after apixban reduced apixaba exposure and facilitated the elimination of apIXaban. Expand
Effect of Activated Charcoal on Rivaroxaban Complex Absorption
TLDR
Results suggest that AC could be used in rivaroxaban overdose and accidental ingestion to antagonise absorption, and significantly reduces exposure to rivroxaban even if AC is administered 8 h after rivARoxaban. Expand
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays
TLDR
This study carried out to determine whether binding of dabigatran on selected insoluble commercial adsorbent material, DOAC‐STOPR, was as efficient as idarucizumab to neutralize the anticoagulant activity of the drug in vitro. Expand
The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph
TLDR
Protamine adversely affects clot initiation time, clot kinetics and platelet function in a dose-dependent manner, which can predispose to bleeding. Expand
Inhibition of Hageman factor activation.
TLDR
Tests with polylysine polymers indicate that inhibitory activity is directly related to molecular size over the molecular weight range of 4000 to 100,000 and that inhibition results from neutralization of the negatively charged sites by the adsorbed inhibtor. Expand
Diagnostic methodologies for circulating anticoagulants.
  • T. Exner
  • Medicine
  • Thrombosis and haemostasis
  • 1995
TLDR
Preliminary evidence is suggested suggesting that various subclasses of LA may account for discrepant results sometimes obtained with different clotting tests, and that even LA as defined may be heterogeneous. Expand
...
1
2
...